Medulloblastoma is a central nervous system tumor, it often recurs, and recurrence, if disseminated, is usually treated with high-dose chemotherapy of cyclophosphamide and etoposide. This therapy is replete with adverse effects, and compliance becomes a significant issue. Metronomic therapy is the safest way to treat malignancies in a very gentle manner. Compliance is very high, and response can be durable and deep. We present a real-life experience of using modified metronomic and targeted antiangiogenesis therapy for children with recurrent/progressive medulloblastoma, a regimen used in a case of a disseminated medulloblastoma patient.
Gharote et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: